ClinicalTrials.gg
Sign In

Fibrolamellar hepatocellular carcinoma clinical trials

The registry lists 20 studies for Fibrolamellar hepatocellular carcinoma across more than 10 countries. 8 are recruiting or about to start. 13 of them are mainly about Fibrolamellar hepatocellular carcinoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-30.

Get an email when these change. Save the Fibrolamellar hepatocellular carcinoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Recruiting
7
Active, not recruiting
5
Completed
3
Terminated
2
Not yet recruiting
1
Suspended
1

Phase

Phase 1
11
Phase 2
10
Phase 3
1

Where

United States
13
France
3
Germany
3
Denmark
1
Spain
1
Canada
1

Who runs them

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (4) · Children's Oncology Group (2) · University Hospital Tuebingen (2) · Memorial Sloan Kettering Cancer Center (2) · Agenus Inc. (1) · Instituto do Cancer do Estado de São Paulo (1) · National Cancer Institute (NCI) (1) · Charite University, Berlin, Germany (1)

What is being tested here

Drugs under test in Fibrolamellar hepatocellular carcinoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Sirpiglenastat102
Cyclophosphamide102
Atezolizumab101
Sorafenib101
Bevacizumab101
Pembrolizumab101
Nivolumab001
Cisplatin011
Botensilimab001
Cobolimab001

Drug classes tested here Immune checkpoint inhibitors 2 open · Angiogenesis inhibitors 1 open

Coming up

1phase 3 study under way
3studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 3, phase 3 first

Who these studies take

Of the 7 Fibrolamellar hepatocellular carcinoma studies recruiting now, 5 (71%) set no upper age limit and 2 (29%) stop at 75 or younger. 5 (71%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 7
AgeWomenMen
102 (29%)2 (29%)
187 (100%)7 (100%)
307 (100%)7 (100%)
405 (71%)5 (71%)
505 (71%)5 (71%)
655 (71%)5 (71%)
755 (71%)5 (71%)
855 (71%)5 (71%)

Across all 20 studies, recruiting or not: 30% stop at 75 or younger and 30% at 65; 60% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

What changed recently

From the registry's own updates since Oct 15, 2026.

Stopped1

Studies

Recruiting first, then most recently updated. Showing 20 of 20. search them.